Hook & thesis
Travere (TVTX) is trading below its 50-day average after a noisy quarter, but the underlying growth engine remains intact: FILSPARI product sales jumped to $200.19 million in Q3, a 120.2% year-over-year increase that accounted for the lion's share of the companys $224.56 million revenue for the quarter. That kind of top-line acceleration is the reason to take a long-side, disciplined trade now.
Yes, the company reported an EPS loss of $0.55 that missed consensus on 11/02/2026, and there is governance and short-interest pressure. But the market cap sits around $4.86 billion with an EV-to-sales of roughly 8.2x, which is a defensible multiple given the steep revenue growth coming from a single, commercial-stage product with clear expansion paths. I recommend a long trade at current levels with a defined stop and two target layers to capture upside while respecting binary risks.
What Travere does and why FILSPARI matters
Travere is a rare-disease biopharma focused on therapies for kidney-related and other rare conditions. The companys recent momentum is driven almost entirely by FILSPARI, which accounted for $200.19M of Q3 2026 sales. FILSPARI grew 120% year-over-year, turning Traveres portfolio into a near-term commercial growth story rather than a research-stage risk.
The market should care because FILSPARI is scaling quickly and translating into meaningful corporate revenues: Q3 revenue was $224.56M, up 36.2% year-over-year, and beat consensus by 16.6%. For a company that spent prior years building out commercial infrastructure, this jump demonstrates successful physician adoption and payer engagement. If FILSPARI maintains even a portion of that growth trajectory over the next several quarters, Traveres top line and valuation multiple both have room to expand.
Hard numbers to anchor the story
- Q3 2026 revenue: $224.56 million (+36.2% YoY).
- FILSPARI sales in Q3 2026: $200.19 million (+120.2% YoY).
- EPS for the quarter: -$0.55 (missed consensus).
- Market cap: ~$4.86 billion; enterprise value: ~$5.34 billion.
- Price-to-sales: ~7.47x; EV-to-sales: ~8.21x.
- 52-week range: $22.59 (low on 01/13/2026) to $68.73 (high on 09/11/2026).
Valuation framing
At a market cap near $4.86B and EV-to-sales around 8.2x, Travere is priced like a growth biopharma with an entrenched commercial product. That multiple looks high on headline metrics, but you need to consider FILSPARIs contribution: it produced $200M in a single quarter and is the main lever for revenue growth. If FILSPARI annualizes at north of $700M-$800M (a plausible path if growth continues), EV-to-forward-sales compresses materially versus current trailing metrics and justifies the present valuation.
Traditional profit multiples are not applicable today (negative EPS), so focus on the revenue growth runway and potential margin expansion as fixed commercial costs are leveraged over higher sales. Cash is limited relative to market cap (reported cash figure in the metrics is small), so capital allocation and free cash flow generation from FILSPARI matter for de-risking the story. Free cash flow in the recent metrics was positive at about $63.8M, which is a constructive sign if it trends up with sales.
Technical and market context
TVTX sits near $50.64, below the 50-day simple moving average of $55.93 and around the 10-day SMA of $50.74. The RSI is neutral at ~44 and MACD shows early bullish momentum. Short interest has been meaningful: recent settlement snapshots show short positions multiple times in the 9M-13M share range with days-to-cover fluctuating and periodic spikes in short volume on high-volume days. That dynamic can accelerate rebounds but also adds volatility.
Trade plan (actionable)
Thesis: FILSPARI's sustained uptake and the potential for improving margins should re-rate the stock over the next several months. We trade the dislocation created by an EPS miss and governance noise while keeping risk tightly managed.
- Entry: $50.64 (current price).
- Stop loss: $42.50. This level sits well below recent short-term support and limits downside if FILSPARI momentum meaningfully slows or if a negative regulatory/governance event hits.
- Target 1 (near-term): $68.73 - reclaim the 52-week high. This is an initial take-profit level for traders who want to bank a re-rating move.
- Target 2 (extended): $85.00 - stretch target if FILSPARI continues accelerating and the company provides bullish guidance or better-than-expected margin/cash-flow updates.
- Position sizing & horizon: This is a long-term trade with an intended duration of long term (180 trading days). The idea is to give FILSPARI time to translate rising physician and payer adoption into sustainable revenue and margin improvement. Scale into the position at the entry and reduce exposure into Target 1, leaving a partial position into Target 2.
Catalysts to watch
- Upcoming quarterly updates and management commentary that provide forward guidance or unit growth trends for FILSPARI.
- New payer coverage announcements or label expansions that broaden the addressable population.
- Conferences or investigator data that reinforce FILSPARIs efficacy/safety profile and encourage broader prescribing.
- Any resolution or clarification around governance or legal inquiries that reduces headline risk and narrows bid-ask spreads.
Risks and counterarguments
Below are the principal risks that could invalidate the trade:
- Execution risk on margins: FILSPARI is currently driving revenue but the company is still posting negative EPS. If cost of goods, SG&A, or R&D ramps faster than revenue or payer rebates compress gross margin, profit conversion could lag and the multiple could re-rate lower.
- Regulatory and competitive pressure: The IgAN and kidney disease treatment landscape is competitive. Recent approvals by larger competitors could blunt FILSPARIs uptake or create pricing pressure.
- Governance/legal headlines: Director stock sales executed under 10b5-1 plans and law firm inquiries have created negative headlines in 2026. Continued governance scrutiny or litigation could sap investor confidence and reduce the stocks multiple.
- High short-interest volatility: Elevated short interest and heavy short-volume days create the possibility of sharp down moves if sentiment shifts, particularly around earnings or guidance misses.
- Single-product concentration: FILSPARI accounts for the majority of current revenue. Any clinical, commercial, or reimbursement setback specific to FILSPARI would have outsized effects on valuation.
Counterargument: The primary counterargument is that the EPS miss signals structural margin problems and that the current FILSPARI growth rate is not durable once comparables increase and payer controls limit new starts. If the market decides that revenue-quality or profit conversion is weaker than the headline growth suggests, the stock could trade materially lower from current levels.
What would change my mind
I would become less constructive if:
- Management signals materially weaker-than-expected guidance for FILSPARI unit growth in upcoming updates, or
- Negative payer decisions materially restrict access, or
- New material litigation or governance findings emerge that threaten operational stability.
Conversely, I would become more bullish if management provides explicit, sustained improvement in gross margins and free cash flow conversion, if FILSPARI quarterly sales grow sequentially above the Q3 trajectory, or if payers broaden access in a way that meaningfully expands the addressable market.
Conclusion
Travere presents a classic growth-biotech trade: a fast-scaling commercial product (FILSPARI) behind meaningful revenue acceleration, but with headline risk from earnings misses and governance noise. For disciplined traders willing to carry risk for up to 180 trading days, the long entry at $50.64 with a stop at $42.50 and staged targets at $68.73 and $85.00 offers an asymmetric risk-reward. Manage size, watch quarterly cadence closely, and treat governance headlines as stop-trigger events rather than excuses to expand a losing position.
Key metrics recap
| Metric | Value |
|---|---|
| Latest quarterly revenue | $224.56M |
| FILSPARI sales | $200.19M |
| EPS (quarter) | -$0.55 |
| Market cap | $4.86B |
| EV / Sales | ~8.2x |
| Current price | $50.64 |